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Abstract 
The development of atherosclerosis is the major etiological factor causing cardiovascular disease and 
constitutes a lipid-induced, chronic inflammatory and autoimmune disease of the large arteries. A 
long standing view of the protective role of B cells in atherosclerosis has been challenged by recent 
studies using B cell depletion in animal models. Whereas complete B cell deficiency increases 
atherosclerosis, depletion of B2 but not B1 cells reduces atherosclerosis. This has led to a re-
evaluation of the multiple potential pathways by which B cells can regulate atherosclerosis, and the 
apparent opposing roles of B1 and B2 cells. B cells, in addition to having the unique ability to 
produce antibodies, are now recognized to play a number of important roles in the immune system, 
including cytokine production and direct regulation of T cell responses. This review summarises 
current knowledge on B cell subsets and functions, and how these could distinctly influence 
atherosclerosis development.  
  
Introduction 
Cardiovascular disease remains a leading cause of death in the developed world and is growing in 
prominence worldwide, with 80% of cardiovascular deaths now occurring in low-middle income 
countries (1). Atherosclerosis constitutes a lipid-induced, chronic inflammatory and autoimmune 
disease of the large arteries (2–5), and is the major underlying cause of heart disease and stroke. 
Control of cholesterol and blood pressure are effective preventive therapies, however further demand 
remains to better target vulnerable, event-inducing plaques, or alternatively reduce development of 
vulnerability. Reducing the associated chronic inflammation sustaining the immune response is an 
important target for scientific and future therapeutic investigation. Despite a long known association 
with atherosclerosis, B cells and antibodies have not always been a research focus. Current 
knowledge from the immunology field defines diverse functions for B cells beyond antibody 
secretion, with multiple subsets playing a role in both innate and adaptive immunity. This, in 
combination with results from mouse models suggesting different types of B cells can enhance as 
well as protect from atherosclerosis, has reignited interest in how these abundant and multifunctional 
cells impact all stages of atherosclerosis development. This review first describes B cell subsets and 
functions, then summarises current views on the potential roles of B cells in atherosclerosis and 
future targets for research that could enable therapeutic targeting. 
B cell subsets and functions 
B cell development and the different B cell subsets characterized are reviewed in detail elsewhere 
(6–8). Broadly, B1 and B2 cells constitute the major 2 groups of B cells and can be considered part 
of the innate and adaptive immune systems, respectively. B2 cells develop in the adult bone marrow 
from hematopoietic stem cells through a well-characterized series of precursor stages (7), whereas at 
least some B1 cells develop in the fetal liver and are self-sustaining in the adult independently of 
HSCs (9,10) (Figure 1A). B cells are primarily found in secondary lymphoid organs (spleen and 
lymph nodes), blood and submucosa of the intestine and lung, but also adipose tissue, aortic 
adventitia and sites of inflammation (11). The primary and unique characteristic of B cells is the 
expression of surface antibody, or B cell receptor, and thus their major function as the source of 
antibody-producing plasma cells. Each B cell clonal lineage develops a unique B cell receptor 
through somatic genome rearrangement of the multi-gene immunoglobulin locus. The binding 
specificity and affinity of the B cell receptor to self or foreign antigen defines the fate of each B cell. 
In the steady state, a system has evolved that provides a repertoire depleted of highly autoreactive 
clones yet robust and diverse enough to target the multitude of potential antigens encountered. Thus, 
multiple checkpoints regulate developing B cells to hone the B cell repertoire through mechanisms 
including receptor editing, anergy and apoptosis (12,13). In addition to antigen, important regulators 
of B cell development and activation include B cell activating factor (BAFF), and a proliferation-
inducing ligand (APRIL) (14). BAFF is essential for B2 cell maturation beyond the Transitional-1 
(T1) stage in the spleen through interaction with BAFF receptor (BAFFR) (15–17). BAFF can also 
regulate survival, activation and function of both B1 and B2 cells through BAFFR and the alternative 
receptor TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor). 
APRIL is a BAFF homologue but interacts only with TACI and a third receptor BCMA (B cell 
maturation antigen), but not BAFFR. TACI is upregulated in activated B cells and plays complex 
roles in B cell proliferation, survival and antibody class switching (18–20) whereas BCMA is 
upregulated on plasma cells and is essential for plasma cell survival in the bone marrow by 
transducing APRIL signals in the plasma cell niche (21,22). 
B1 cells play a major role in maintaining the barrier function of mucosal surfaces and possess B cell 
receptors with germline-encoded specificities for common pathogen-associated epitopes and rarely 
undergo B cell receptor editing or maturation, thus are as much part of the innate as the adaptive 
immune system. B1 cells are the source of natural antibodies, which are produced independently of 
any external antigens. One major family of these epitopes are oxidation-associated epitopes and 
include phosphorylcholine (PC) and malondialdehyde (MDA) (23). Such epitopes are common in 
endogenous debris such as apoptotic and necrotic cells and modified lipoprotein particles, e.g. 
oxidized low density lipoprotein (oxLDL). Thus, natural antibodies (and other antibodies targeting 
these antibodies) play an important role in homeostatic clearance of dead cells and other debris 
including oxLDL, and may contribute significantly to clearance pathways in atherosclerosis. 
Mature B2 cells recirculate via the blood through secondary lymphoid organs where they may 
encounter antigens captured and displayed by macrophages and dendritic cells, in general as part of 
immune complexes with (presumably) low affinity, natural or previously produced antibodies. 
Depending on other signals and the precise location, B2 cells are then activated and proliferate, 
leading variously to short-lived plasma cells, long-lived plasma cells that migrate to the bone marrow 
and memory B cells that enable life-long immunological memory and more rapid responses upon 
subsequent antigen encounters (24) (Figure 1A). Bone marrow plasma cells can persist for years and 
continue producing antibodies, but re-exposure to the same antigens stimulates memory B cell 
activation and formation of new plasma cells. Marginal zone B2 cells bridge the functions of B1 and 
follicular B2 cells, possessing somatically rearranged B cell receptors but having a memory-like 
phenotype that allows a more rapid B1-like response that can be activated by innate signals like Il-5 
or toll-like receptor ligands. In addition to developmental antibody receptor diversification, mature 
B2 cells selected and activated by the presence of cognate antigen undergo two further changes to 
their B cell receptor (antibody) - class switching of the Fc region and mutagenesis of the antigen 
binding Fab region to enhance affinity. Affinity maturation occurs in proliferating activated B cells 
in the germinal centers (GC) of secondary lymphoid organs where higher affinity clones prevail 
through competition for antigen immobilized on follicular dendritic cells (25). 
Antibodies play a primary effector function in neutralizing and clearing pathogens, pathogen-
associated molecules and infected cells through a range of mechanisms, including antibody-
dependent cellular cytoxicity, recruitment of the complement system  and promoting phagocytosis 
(26–28). Antibodies also influence innate immune function and phenotype, particularly macrophage 
inflammatory activation through the Fc region binding to Fc receptors on the cell surface (26). 
B cells, like most immune cells, produce a range of cytokines with potent and diverse effects. For B 
cells, these include most prominently Il-6, Il-10 and TNF (29). B cells also respond to many 
cytokines including Il-6, TNF, IFN-α, Il-4, Il-5, and IFN-γ. More recently, a distinct subset of spleen 
B cells has been shown to be capable of GM-CSF production and that these cells can significantly 
influence innate immune functions (30). Alternatively, B cell derived MCP-3 (Ccl7) is critical to 
monocyte mobilization in response to myocardial infarction with B cell depletion leading to reduced 
infarct area and improved heart function (31). 
B cells also regulate their adaptive immune counterparts, T cells, through antigen presentation and 
co-stimulation (32). In general, B cells are not phagocytic like myeloid antigen presenting cells, and 
only antigen endocytosed while bound to the B cell receptor (surface antibody) is processed and 
presented on B cell MHCII molecules to helper CD4+ T cells. Although dendritic cells act as 
primary activators of helper T cells, in many cases B cell – helper T cell interactions are critical in 
sustaining and regulating the nature of both T cell and B cell responses, for example in response to 
lower antigen levels (33). 
Not all B cells require the presence of cognate antigen or the presence of helper T cells for their 
activation and differentiation into plasma cells. B1 cells and certain B2 cell subsets, such as marginal 
zone B cells, can be activated directly by pathogen-associated molecular patterns, for example toll-
like receptor ligands, or cytokines such as IFN-α, Il-1β and Il-5 (34,35). In contrast, responses to 
protein antigens are commonly T cell dependent and require ongoing contact with antigen, 
costimulation and cytokines; the latter two signals received from specialized follicular helper T cells. 
BAFF and APRIL also play prominent roles in B cell activation in addition to being critical to 
homeostatic maintenance (16,17,36). Thus, both innate and adaptive immune pathways could lead to 
B cell activation in atherosclerosis (Figure 1B). 
Association of B cells and autoantibodies with atherosclerosis 
The humoral nature of B cell antibody responses suggests a remote regulation of atherosclerosis is 
most likely and most important. Furthermore, a number of other remote pathways negate a need for 
the presence of B cells within or adjacent to plaques for them to be important. These include T cell 
responses in spleen and lymph node, regulation of innate cell differentiation, monocyte mobilization 
from bone marrow, and their presence at alternative sites of cardiovascular disease-associated 
inflammation such as adipose tissue. Nevertheless, B cells can be found in plaques but are more 
often found at adventitial sites close to plaques (37–39). Initial reports suggested these cells may be 
plasma cells, whereas a recent report concluded that these B cells are most likely B2-derived 
plasmablasts, with evidence of local affinity maturation occurring in both adventitia and plaque, and 
the presence of a limited number of class-switched clones (40). The adventitia is a well-recognised 
site for immune responses (41), and advanced human and mouse atherosclerosis leads to the 
development of tertiary lymphoid organs in the adjacent adventitia (38,42). This suggests a potential 
for local B cell responses in advanced human atherosclerosis and thus ongoing regulation of plaque 
status. Whether adventitial immune responses and cell accumulation also occur in symptomatic 
coronary and carotid plaques is unclear, however it is easy to envisage aorta-originating B cell and T 
cell responses regulating plaques at other sites. Very recently, a study examining whole blood global 
gene co-expression identified a strong indication of B cell dysregulation in coronary heart disease 
patients compared to controls (43) and another showed activated CD86+ B cells associate with a 
higher risk of stroke (44). 
The presence of antibodies within atherosclerotic plaques is much more prominent than B cells 
themselves, with abundant IgM and IgG detected in human and mouse plaques (39,45,46).  
Circulating levels of modified LDL-reactive antibodies also associate with atherosclerosis (47,48), as 
do those to heat shock protein 65 (49). Levels of both natural IgM antibodies and adaptive IgG 
antibodies reacting with moieties found in modified LDL and on apoptotic cells, e.g. phophocholine 
or malondialdehyde, are associated with atherosclerotic burden in many studies, although not all 
(50–52). Interestingly, IgM levels decline with age (53), consistent with studies showing an inverse 
correlation with disease and extensive experimental evidence of its protective influence (46,54). 
Overall, the prevailing view is that anti-oxLDL IgG is positively correlated whereas IgM is 
negatively correlated; however doubt still remains, particularly in the case of IgG. Equally, 
prospective studies have shown mixed results (52). For example, anti-modified LDL antibodies 
predicted myocardial infarction in type II diabetes patients in the VADT study (55), but there was no 
prognostic value in the EPIC-Norfolk study (56). A further impact of B cells on atherosclerosis is the 
association of other autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus 
erthyramatous and Sjorgren’s syndrome (57,58) with an increased risk of cardiovascular disease. 
How the presence of these autoimmune diseases influences cardiovascular disease is complex, but 
cross-reactivity of autoantibodies is one contributory mechanism as well as systemic pro-
inflammatory cytokines that may be induced in part dependently on autoantibodies. In RA, the 
correlation between oxLDL IgG antibodies and atherosclerosis seems more consistent (59–61). 
Recently, in SLE patients, levels of autoantibodies to dsDNA and Cardiolipin were associated with 
higher levels of noncalcified plaques, potentially more prone to rupture (62) and a previously 
unappreciated pro-atherosclerotic role for IgE antibodies was demonstrated in ApoE-/- mice (63). The 
functional roles and overall influence of antibodies in atherosclerosis are further discussed below. 
 
B cells regulate atherosclerosis – Evidence from mouse models 
Given the diverse functions and wide ranging impact of B cells on immune responses, it is 
unsurprising that B cell regulation of atherosclerosis is complex to dissect. Past studies suggesting a 
solely protective role for B cells in atherosclerosis must now be reinterpreted based on the divergent 
roles of different B cell subsets and their antibodies. The increased atherosclerosis in B cell-deficient 
(µMT), atherosclerotic-prone ApoE-/- mice (64) and splenectomized mice (65) could be primarily 
due to the lack of B1 cells and natural IgM (46,54), which plays a prominent role in opsonisation and 
non-inflammatory removal of oxLDL as well as apoptotic cells. In contrast to genetic deficiency of 
all B cells, anti-CD20 antibody treatment, which preferentially depletes B2 cells, leaving B1 cells 
largely intact, reduces atherosclerosis (66,67). Corroborating these studies, the specific lack of 
mature B2 cells in ldlr-/- mice transplanted with B cell activating factor receptor (BAFFR)-deficient 
bone marrow reduces atherosclerosis (68). The same is true for BAFFR-/- mice on the ApoE-/- 
background (69) and B cell-specific BAFFR deficiency (68). Resupplementation of B cell-deficient 
mice with spleen B2 cells reverses the reduction of atherosclerosis (67). However, other groups have 
shown protective effects of transferred spleen B cells (65,70), suggesting as yet unclear complexities 
and multiple potential mechanisms for B2 cell regulation of atherosclerosis. Doran et al (70) showed 
that the ability to home to the aorta through CCL20-CCR6 signaling was key for atheroprotection. It 
is not clear if this property was important to recruit a certain subset or to the localization of B cells in 
general to the adventitia. Further fractionation of B2 (or spleen) subsets, or transfer of B cells from 
appropriate knockout mice, will be necessary to determine these remaining questions. 
 
Mechanisms for B cell regulation of atherosclerosis 
There are 3 major modalities by which B cells could influence atherosclerosis, 1) through antibodies, 
2) through regulation of T cell responses via cell-cell contact, and 3) through production of 
cytokines. These different modalities may act through a variety of pathways and each has both anti- 
and pro- atherogenic potential. 
1) Multiple roles of antibodies in atherosclerosis 
Past studies have provided many useful insights into the potential roles for autoantibodies in 
atherosclerosis. However, the lack of complete discrimination between natural or innate-derived and 
adaptive antibodies, the use of immunization strategies that also stimulate natural antibody and 
regulatory T cell-mediated immune responses (71), and a focus on oxLDL targeting antibodies (72), 
means that the overall influence of B cell antibodies is still unclear. The most recognized and studied 
autoantigen in atherosclerosis is modified LDL, with epitopes from various forms targeted both by 
natural antibodies and B2 cell-derived, class-switched IgG antibodies. Hsp60 and 65, as well as β2 
glycoprotein I, are further autoantigens (73). Passive Ig transfer (intravenous immunoglobulin; IVIg) 
suppresses atherosclerosis (74). IVIg, used in other autoimmune diseases and transplant patients, is 
hypothesised to work through differential sialylation of the Fc portion, leading to 
immunosuppressive pathways via IL-33, Il-4 and induction of macrophage FcRIIb (75) as well as 
through induction of regulatory T cells (76). Although a number of modified LDL or apoB peptide 
based active immunization strategies consistently reduce atherosclerosis (77,78), their effects are 
primarily due to increased regulatory T cell responses, enhanced natural antibody production and a 
shift to Th2 IgG responses, thus may not represent endogenous humoral responses (71,79). Indeed, 
both immunogenic adjuvant-containing (77,78)  and tolerogenic (e.g. mucosal or oral) formulations 
(79,80) lead to enhanced Treg levels and reduced atherosclerosis. In contrast, immunization with 
Hsp65 can enhance atherosclerosis (81–83), whereas tolerogenic strategies targeting Hsp65 reduce 
atherosclerosis (84–86). Immunization against β2-GPI can also enhance atherosclerosis (87). The 
consequences of endogenous antibody responses are far better understood for IgM antibodies than 
IgG and other isotypes, as exemplified by the E06 monoclonal phospholipid-reactive IgM (88). It is 
likely that enhanced clearance of oxLDL, preventing its accumulation in plaque and foam cell 
formation, is a major mechanism for the action of B1 cell derived IgM (89). Interestingly, very 
recent data suggests that excessive IgM accumulation in plaque bound to necrotic and lipid debris 
could in fact be pro-inflammatory (90), emphasising the need for further investigation. A major 
effector pathway for IgG antibodies linked to atherosclerosis are the Fcγ receptors, of which there are 
both pro-inflammatory activating receptors (I, IIa, III and IV) and an inhibitory receptor (IIb) 
(26,91). A pathogenic role for IgG antibodies/immune complexes in atherosclerosis is supported by 
findings that mice lacking activating, pro-inflammatory Fcγ (IgG) receptors have reduced 
atherosclerosis (92,93), whereas mice lacking the inhibitory FcγRIIb have enhanced atherosclerosis 
(94). Immune complexes are known to activate macrophages (95), a central mediator of plaque 
formation via Fc receptors, and oxLDL immune complexes can promote foam cell formation. 
Different IgG isotypes have varying affinities for Fc receptors and thus different activatory capacity, 
for example IgG2a/c (different strains express a or c isoforms) in mice is highly activatory (26). 
IgG2c is mainly induced in association with Th1 type responses such as those which dominate 
atherosclerosis, accordingly anti-oxLDL IgG2c is commonly found in atherosclerotic mice 
(46,66,68,92). In addition, the pathogenic or protective role of the targeted antigen (e.g. oxLDL vs 
heat-shock proteins) could strongly influence the effects of humoral responses against it, i.e. 
targeting the clearly pro-atherogenic oxLDL autoantigen may well be protective, whereas 
endogenous responses to distinct autoantigens may in contrast be pathogenic. Thus, the 
consequences of endogenous IgG responses in atherosclerosis remain ill-defined and methods to 
specifically target them must be developed to improve our understanding. 
2) B cell regulation of atherogenic T cells 
Results from B2 cell depletion models (66–68) support a role for B2 cell potentiation of pro-
atherogneic CD4+ T cell effector responses. Each of these studies was associated with significantly 
reduced numbers of T cells in plaques as well as systemic decreases in pro-atherosclerotic IFN-γ 
producing T cells, whereas complete B cell deficiency results in enhanced plaque T cell levels (65). 
These B cell-deficient (µMT) mice have defective Th2 (Il-4) differentiation capacity due to an effect 
on DCs (96), which may partly be due to lack of antibody-mediated uptake and lysosomal targeting 
(97). B cell depletion therapy is also effective in reducing other T cell dependent chronic diseases 
such as multiple sclerosis and rheumatoid arthritis (reviewed in (98)). Conventional CD11chi 
dendritic cells are now recognised as the primary and non-redundant antigen presenting cells 
activating, as well as maintaining, naïve T cells. However, macrophages and B cells can also play 
prominent roles in presenting antigen to effector T cells and influencing the nature (Th1, Th2, Th17, 
Treg), power and longevity of effector T cell responses (98). It has not yet been investigated whether 
MHCII-mediated antigen presentation by B cells is important for their stimulation of pro-atherogenic 
CD4+ T cell responses. Co-stimulatory molecules such as CD40 and OX40, or cytokines like TNF or 
IL-6 are also likely candidates for future investigation. A recent study investigating RP105, a TLR 
receptor regulator, also supports an important role for TLR-mediated regulation of B cells in 
atherosclerosis (99). 
3) B cell-derived cytokines and atherosclerosis 
Kyaw et al (67) showed that transferred B2 cells promoted atherosclerosis in T cell (and B cell) 
deficient RAG2-/-/ApoE-/- mice, although to a lesser extent than in T cell-sufficient mice. This 
suggests there are both T cell dependent and independent mechanisms involved. Beyond antibodies, 
B cells are now recognised to modulate immune responses, particularly those initiating in the spleen, 
through cytokines. For example, B cells are a major source of MCP-3 (Ccl7) in response to 
myocardial infarction and promote heart injury through monocyte mobilization into the infarct site 
(31). Although not yet investigated in atherosclerosis, GM-CSF+ B cells, also characterized as B1-
like plasmablasts resident in the spleen marginal zone, could potentially play an important role in 
atherosclerosis. In contrast to these potentially pro-atherogenic B cells, Il-10 producing B cells are 
likely protective. Although rare ‘regulatory’ B cell subsets characterized by high CD1d, CD19 and 
CD5 expression are important IL-10 producers (also called B10 cells) (32), other groups suggest that 
more common B cell subsets including marginal zone and B1 cells may potentially produce IL-10 
given the correct environmental stimuli, such as TLR ligands (35). Indeed, switching B cells between 
Il-10 and Il-6 production is associated with functional regulation of experimental autoimmune 
encephalomyelitis (EAE), a model of multiple sclerosis (29). B cells are also reported to express 
further cytokines such as TNF, which may be important in regulating T cell responses (100). Thus B 
cell cytokine-mediated regulation of atherosclerosis merits further attention in future studies. 
Conclusion 
The characterization of heterogeneity within B cells has led to a better appreciation that B cells can 
play multiple roles in atherosclerosis, with different subsets playing potentially opposing roles. 
Recent studies in mice have revealed the source of B cell protective immunity as primarily IgM, 
strongly supported by numerous clinical studies assessing human circulating anti-oxLDL IgM levels, 
whereas despite multiple lines of indirect evidence, the jury is still out on the functional roles of IgG 
and the nature of pro-atherogenic B cell immunity. Current research is focused on determining 
through which of the distinct functional pathways B cells regulate atherosclerosis development and 
whether these can be translated into therapeutic strategies. An important question will be how closely 
the roles of murine B cell subsets match their human counterparts, given various differences in cell 
and antibody isotype subsets. Therapeutically, the BAFF/APRIL system may be a fruitful area of 
research; establishing their role in endogenous atherosclerotic B cell (and potentially other immune 
cell) responses could be important in both understanding the underlying causes and mechanisms, and 
in therapeutic interventions, since a number of BAFF and APRIL targeting monoclonal antibodies 
have been developed and are already in clinical trials for cancer and autoimmune diseases. This is 
further supported by data showing upregulated BAFF and APRIL in human plaques (101) and the 
association of increased BAFF with myocardial infarction (31). 
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A. B cell development and subsets. B1 cells develop primarily from fetal liver and self-maintain 
in the adult. B1 cells are the source of natural IgM antibodies that target antigens such as oxidized 
phospholipids. B2 cells develop from adult bone marrow stem cells and undergo a series of 
differentiation steps in the bone marrow, then leave as immature/transitional B cells and further 
differentiate into either marginal zone or follicular B cells in the spleen. B2 cell activation leads to 
short-lived plasma cell differentiation or, in the case of T cell dependent responses, germinal centre 
formation, which results in affinity maturation of the B cell clone and formation of memory B cells 
and long-lived plasma cells, which can persist in specific bone marrow niches until ntigen 
reencounter. B. B cell regulation of atherosclerosis. Natural antibodies and other IgM targeting 
oxLDL, primarily but not exclusively from B1 cells, is thought to be atheroprotective. The potential 
pro-atherogenic functions of B2 cells include production of IgG2 antibodies that activate 
macrophages via Fc receptors, activation of pro-atherogenic Th1 CD4 T cells, or production of pro-
inflammatory T cells. B cells may act remotely from peripheral lymphoid organs or locally from the 
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